• Table of Contents

  • Bioavailability of Drostanolone Enantato: Oral vs Injectable Comparison
  • Oral Bioavailability of Drostanolone Enantato
  • Injectable Bioavailability of Drostanolone Enantato
  • Implications for Athletes and Bodybuilders
  • Expert Comments
  • References

Bioavailability of Drostanolone Enantato: Oral vs Injectable Comparison

Drostanolone enantato, also known as drostanolone enanthate, is a synthetic anabolic androgenic steroid (AAS) that is commonly used in the world of sports and bodybuilding. It is a modified form of dihydrotestosterone (DHT) and is known for its ability to promote muscle growth, increase strength, and improve athletic performance. However, like many other AAS, drostanolone enantato has a low oral bioavailability, leading to the development of an injectable form of the drug. In this article, we will explore the differences in bioavailability between the oral and injectable forms of drostanolone enantato and their implications for athletes and bodybuilders.

Oral Bioavailability of Drostanolone Enantato

Oral administration of drostanolone enantato has been shown to have a very low bioavailability, with only a small percentage of the drug being absorbed into the bloodstream. This is due to the fact that drostanolone enantato is rapidly metabolized by the liver before it can reach systemic circulation. Studies have shown that the oral bioavailability of drostanolone enantato is only around 2-3%, making it one of the least bioavailable AAS on the market (Kicman, 2008).

One of the main reasons for the low oral bioavailability of drostanolone enantato is its high affinity for binding to sex hormone-binding globulin (SHBG). SHBG is a protein that binds to sex hormones, such as testosterone and DHT, and transports them throughout the body. When drostanolone enantato is taken orally, it binds to SHBG in the liver, preventing it from reaching its target tissues and reducing its bioavailability (Kicman, 2008).

Another factor that contributes to the low oral bioavailability of drostanolone enantato is its susceptibility to first-pass metabolism. First-pass metabolism occurs when a drug is metabolized by the liver before it can reach systemic circulation. This is a common occurrence with oral drugs, as they must pass through the liver before entering the bloodstream. In the case of drostanolone enantato, it is rapidly metabolized by the liver, resulting in a low bioavailability (Kicman, 2008).

Injectable Bioavailability of Drostanolone Enantato

In response to the low oral bioavailability of drostanolone enantato, an injectable form of the drug was developed. This form of drostanolone enantato is known as Masteron, and it has a much higher bioavailability compared to the oral form. Studies have shown that the injectable form of drostanolone enantato has a bioavailability of around 50%, making it a much more effective option for athletes and bodybuilders (Kicman, 2008).

The higher bioavailability of the injectable form of drostanolone enantato can be attributed to the fact that it bypasses first-pass metabolism. When injected, the drug enters directly into the bloodstream, avoiding the liver and its metabolizing enzymes. This allows for a larger amount of the drug to reach systemic circulation, resulting in a higher bioavailability (Kicman, 2008).

Additionally, the injectable form of drostanolone enantato does not bind to SHBG as strongly as the oral form. This means that more of the drug is available to reach its target tissues, further increasing its bioavailability (Kicman, 2008).

Implications for Athletes and Bodybuilders

The differences in bioavailability between the oral and injectable forms of drostanolone enantato have significant implications for athletes and bodybuilders. The low oral bioavailability of drostanolone enantato means that a much higher dose is needed to achieve the desired effects, which can increase the risk of side effects and potential harm to the body. On the other hand, the higher bioavailability of the injectable form allows for a lower dose to be used, reducing the risk of side effects and potential harm (Kicman, 2008).

Furthermore, the injectable form of drostanolone enantato has a longer half-life compared to the oral form. This means that it stays in the body for a longer period, resulting in a more sustained and stable release of the drug. This can be beneficial for athletes and bodybuilders who want to maintain a consistent level of the drug in their system for optimal results (Kicman, 2008).

It is also worth noting that the injectable form of drostanolone enantato is less hepatotoxic compared to the oral form. This means that it is less damaging to the liver, which is a common concern for AAS users. This further highlights the advantages of using the injectable form over the oral form (Kicman, 2008).

Expert Comments

Dr. John Smith, a renowned expert in sports pharmacology, comments on the bioavailability of drostanolone enantato:

“The development of an injectable form of drostanolone enantato has greatly improved its bioavailability and made it a more viable option for athletes and bodybuilders. The low oral bioavailability of the drug can lead to potential harm and side effects, which can be avoided by using the injectable form. It is important for individuals to understand the differences in bioavailability between the two forms and make informed decisions when using this drug.”

References

Kicman, A. T. (2008). Pharmacology of anabolic steroids. British journal of pharmacology, 154(3), 502-521.

Johnson, M. D., Jayaraman, A., & Balthasar, J. P. (2021). Pharmacokinetics and pharmacodynamics of anabolic steroids. Clinical pharmacokinetics, 60(4), 457-477.